- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03486912
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis (FALCON 2)
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Fukushima, Japan, 960-1295
- Fukushima Medical University Hospital
-
-
Fukuoka
-
Kurume, Fukuoka, Japan, 8300011
- Kurume University Hospital
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 236-0004
- Local Institution - 0055
-
-
Nara
-
Kashihara, Nara, Japan, 6348522
- Local Institution - 0072
-
-
Tokyo
-
Minato, Tokyo, Japan, 105-8470
- Toranomon Hospital
-
Shinjuku-ku, Tokyo, Japan, 1600016
- Keio University Hospital
-
-
-
-
Alabama
-
Madison, Alabama, United States, 35758
- North Alabama Health Research, LLC
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- Local Institution - 0005
-
Phoenix, Arizona, United States, 85013
- Local Institution - 0088
-
Phoenix, Arizona, United States, 85054
- Local Institution - 0006
-
Tucson, Arizona, United States, 85712
- Local Institution - 0090
-
-
California
-
Corona, California, United States, 92879
- Kindred Medical Institute for Clinical Trials
-
Coronado, California, United States, 92118
- Local Institution - 0092
-
La Jolla, California, United States, 92037
- Local Institution - 0038
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, United States, 90036
- Local Institution - 0017
-
Los Angeles, California, United States, 90067-2015
- GastroIntestinal BioSciences
-
Montclair, California, United States, 91763
- Catalina Research Institute
-
Oakland, California, United States, 94611
- Kaiser Permanente
-
Oxnard, California, United States, 93030
- Diverse Research Solutions
-
Pasadena, California, United States, 91105
- Huntington Medical Research Institutes - HMRI Liver Center
-
Pasadena, California, United States, 91105
- Local Institution - 0020
-
Redwood City, California, United States, 94063
- Local Institution - 0073
-
Rialto, California, United States, 92377
- Local Institution - 0012
-
San Clemente, California, United States, 92673
- Local Institution - 0089
-
San Diego, California, United States, 92105
- Local Institution
-
San Diego, California, United States, 92123
- Local Institution - 0014
-
San Francisco, California, United States, 94115
- Local Institution - 0068
-
-
Connecticut
-
Bridgeport, Connecticut, United States, 06610
- Local Institution - 0042
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Local Institution
-
-
Florida
-
Coral Gables, Florida, United States, 33134
- Local Institution - 0079
-
Cutler Bay, Florida, United States, 33189
- Top Medical Research
-
Homestead, Florida, United States, 33030
- Clinical Research of Homestead
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic - Jacksonville
-
Lakewood Ranch, Florida, United States, 34211
- Local Institution - 0001
-
Miami, Florida, United States, 33144
- A+ Research
-
Miami, Florida, United States, 33157
- IMIC Research
-
Miami, Florida, United States, 33136
- Local Institution - 0003
-
Ocoee, Florida, United States, 34761
- Sensible Healthcare
-
Orlando, Florida, United States, 32806
- Local Institution - 0081
-
Tampa, Florida, United States, 33606
- Local Institution
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
- Local Institution
-
Marietta, Georgia, United States, 30060
- Local Institution - 0108
-
-
Louisiana
-
Marrero, Louisiana, United States, 70072
- Tandem Clinical Research
-
New Orleans, Louisiana, United States, 70112
- Tulane University Health Sciences Center
-
New Orleans, Louisiana, United States, 70121
- Local Institution - 0026
-
-
Maryland
-
Baltimore, Maryland, United States, 21202
- Local Institution - 0010
-
Catonsville, Maryland, United States, 21228
- Local Institution - 0058
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston Medical Center
-
Fall River, Massachusetts, United States, 02721
- NECCR PrimaCare Research
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Missouri
-
Chesterfield, Missouri, United States, 63005
- Clinical Research Professionals
-
Kansas City, Missouri, United States, 64111
- Local Institution - 0031
-
Saint Louis, Missouri, United States, 63110
- Saint Louis University
-
-
New York
-
Buffalo, New York, United States, 14203
- University at Buffalo
-
Manhasset, New York, United States, 11030
- Northwell Health
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
New York, New York, United States, 10003
- Mount Sinai Hospital
-
New York, New York, United States, 10016
- Local Institution - 0036
-
-
North Carolina
-
Butner, North Carolina, United States, 27509-1626
- Local Institution - 0067
-
Charlotte, North Carolina, United States, 28204
- Local Institution - 0064
-
Concord, North Carolina, United States, 28027
- Northeast GI Research Division
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Local Institution - 0009
-
Pittsburgh, Pennsylvania, United States, 15213
- Local Institution - 0004
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37421
- Local Institution
-
Germantown, Tennessee, United States, 38138
- Local Institution - 0046
-
Hermitage, Tennessee, United States, 37076
- Local Institution - 0041
-
Nashville, Tennessee, United States, 37232-5280
- Vanderbilt University Medical Center
-
-
Texas
-
Arlington, Texas, United States, 76012
- Texas Clinical Research Institute
-
Austin, Texas, United States, 78757
- Local Institution - 0066
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
Dallas, Texas, United States, 75246
- Texas Digestive Disease Consultants - Dallas
-
Dallas, Texas, United States, 75203
- Local Institution - 0051
-
Dallas, Texas, United States, 75234
- Local Institution - 0053
-
Fort Worth, Texas, United States, 76104
- Local Institution - 0084
-
Houston, Texas, United States, 77002
- Local Institution - 0002
-
Houston, Texas, United States, 77030
- Local Institution - 0057
-
Houston, Texas, United States, 77030
- Local Institution - 0063
-
San Antonio, Texas, United States, 78215
- Local Institution - 0028
-
San Antonio, Texas, United States, 78229
- Local Institution - 0011
-
San Antonio, Texas, United States, 78229
- Local Institution - 0102
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- University of Vermont Medical Center
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University Of Virginia Health System
-
Falls Church, Virginia, United States, 22042
- Inova Fairfax Hospital
-
Manassas, Virginia, United States, 20110
- Gastroenterology Associates, PC
-
Norfolk, Virginia, United States, 23502
- Local Institution - 0069
-
Reston, Virginia, United States, 20191
- The Gastroenterology Group
-
Richmond, Virginia, United States, 23226
- Bon Secours Liver Institute of Richmond
-
Richmond, Virginia, United States, 23249
- Local Institution - 0077
-
Richmond, Virginia, United States, 23298
- Local Institution - 0050
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Liver biopsy performed within 6 months (26 weeks) prior to the screening period. If historical biopsy is not available, a liver biopsy will be performed during the screening period. Biopsy must be consistent with NASH and cirrhosis according to the NASH CRN classification, as assessed by the central reader
- Must be taking anti-diabetic, anti-obesity, or anti-dyslipidemic medications must have been on stable regimens for at least 3 months (12 weeks) (6 weeks for statins) prior to and during the screening period
- Participants taking vitamin E at doses greater than or equal to (>=) 800 IU/day must have been on stable doses for at least 6 months (26 weeks) prior to and during the screening period. Vitamin E treatment (>=800 IU/day) must not have been initiated after the qualifying liver biopsy was performed
Exclusion Criteria:
- Other causes of liver disease (e.g., alcoholic liver disease, hepatitis B virus infection, chronic hepatitis C virus infection [HCV], autoimmune hepatitis, drug-induced hepatotoxicity, Wilson disease, α-1-antitrypsin deficiency, iron overload, and hemochromatosis); participants with HCV sustained viral response (undetectable HCV RNA) for at least 2 years prior to biopsy confirming study eligibility may be eligible
- Current or past history of hepatocellular carcinoma (HCC)
- Past or current evidence of hepatic decompensation (e.g., ascites, variceal bleeding, hepatic encephalopathy and/or spontaneous bacterial peritonitis) or liver transplantation
- Medical history of gastroesophageal varices, except if esophagogastroduodenoscopy [EGD] performed within 12 months prior to the Screening Period has shown <= Grade 1 varices
Other protocol-defined inclusion/exclusion criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
Specified dose on specified days.
|
EXPERIMENTAL: BMS-986036 Dose Level 1
|
Specified dose on specified days.
Other Names:
|
EXPERIMENTAL: BMS-986036 Dose Level 2
|
Specified dose on specified days.
Other Names:
|
EXPERIMENTAL: BMS-986036 Dose Level 3
|
Specified dose on specified days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 48
Time Frame: From first dose to 48 weeks after first dose
|
An improvement in fibrosis is defined as a decrease of fibrosis by ≥1-stage in the NASH Clinical Research Network (CRN) Fibrosis Score at week 48 in liver biopsy. Worsening of NASH is defined as an increase of the nonalcoholic fatty liver disease activity score (NAS) by ≥ 1-stage. Worsening of NASH is defined as an increase of the nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) by ≥1 point. Worsening of fibrosis is defined as an increase of fibrosis by ≥1 point as determined by the NASH CRN Fibrosis Score. |
From first dose to 48 weeks after first dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Ishak Fibrosis Score at Week 48
Time Frame: From first dose to 48 weeks after first dose
|
An improvement in Ishak fibrosis is defined as a decrease of fibrosis by ≥ 1-stage in the Ishak fibrosis score at week 48 in liver biopsy.
ISHAKs uses a 0-6 scale: 1: centrilobular pericellular fibrosis, 2: centrilobular and periportal fibrosis, 3: bridging fibrosis (few bridges), 4: bridging fibrosis (many bridges), 5: early or incomplete cirrhosis, 6: established or advanced cirrhosis.
|
From first dose to 48 weeks after first dose
|
The Percentage of Participants With Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) or NASH Improvement at Week 48
Time Frame: From first dose to 48 weeks after first dose
|
The percentage of participants who achieved a ≥1-stage improvement in fibrosis without worsening of NASH or NASH improvement with no worsening of fibrosis at week 48 in liver biopsy.
Improvement in fibrosis is defined by the NASH Clinical Research Network (CRN) Fibrosis Score.
Improvement in NASH is defined by a ≥2-stage decrease in the nonalcoholic fatty liver disease activity score (NAS).
NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
|
From first dose to 48 weeks after first dose
|
The Percentage of Participants Who Achieved >=1 Point Improvement in Fibrosis at Week 48
Time Frame: From first dose to 48 weeks after first dose
|
An improvement in fibrosis is defined as a decrease of ≥ 1-stage in the non-alcoholic steatohepatitis clinical research network (NASH CRN) Fibrosis Score at week 48 in liver biopsy.
NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
|
From first dose to 48 weeks after first dose
|
The Percentage of Participants With Any Improvement in Collagen Proportionate Area (CPA) at Week 48
Time Frame: From first dose to 48 weeks after first dose
|
An improvement in CPA is defined as any decrease in CPA at week 48 in liver biopsy.
|
From first dose to 48 weeks after first dose
|
The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution at Week 48
Time Frame: From first dose to 48 weeks after first dose
|
NASH resolution defined by the nonalcoholic fatty liver disease activity score (NAS) component of ballooning = 0 and inflammation = 0-1 at week 48 in liver biopsy.
Ballooning = 0 (none) inflammation = 0 (none) - 1 (Grade <2).
|
From first dose to 48 weeks after first dose
|
The Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Improvement at Week 48
Time Frame: From first dose to 48 weeks after first dose
|
The percentage of participants with NASH improvement at week 48 in liver biopsy.
NASH improvement is defined as a reduction of nonalcoholic fatty liver disease activity score (NAS) by ≥ 2 points with contribution from > 1 NAS component.
The NASH CRN system assesses liver biopsies for degree of steatosis (0-3), lobular inflammation (0-3), hepatocellular ballooning (0-2), and fibrosis (0-4).
The 3 categories are added together in an unweighted fashion to determine the NAS, which ranges from 0 to 8.
|
From first dose to 48 weeks after first dose
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MB130-069
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonalcoholic Steatohepatitis
-
Duke UniversityCompletedLiver Diseases | Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | Nonalcoholic Fatty LiverUnited States
-
Gilead SciencesCompletedNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)United States, New Zealand
-
National Institute of Diabetes and Digestive and...CompletedNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)United States
-
Polaris GroupRecruiting
-
Corcept TherapeuticsRecruitingNonalcoholic Steatohepatitis (NASH)United States
-
PerspectumRecruitingNASH - Nonalcoholic SteatohepatitisUnited States
-
Metacrine, Inc.Completed
-
Cascade Pharmaceuticals, IncLaboratory Corporation of AmericaCompletedNonalcoholic Steatohepatitis (NASH)United States
-
Poxel SACompletedNASH - Nonalcoholic SteatohepatitisUnited States
-
RWTH Aachen UniversityCompletedNASH - Nonalcoholic SteatohepatitisSweden, Austria, Germany
Clinical Trials on BMS-986036
-
Bristol-Myers SquibbCompletedDiabetes Mellitus Type 2United States, Canada
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompletedNAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic SteatohepatitisHungary, Czechia
-
Bristol-Myers SquibbCompletedNonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | Liver Fibrosis | Hepatic CirrhosisUnited States
-
Bristol-Myers SquibbCompletedMetabolicsUnited States
-
Bristol-Myers SquibbWithdrawnHealthy ParticipantsChina, Korea, Republic of
-
Bristol-Myers SquibbCompletedNon-Alcoholic SteatohepatitisUnited States
-
Bristol-Myers SquibbCompletedNon-Alcoholic SteatohepatitisUnited States
-
Bristol-Myers SquibbCompletedModerate Liver Impairment | Severe Liver ImpairmentUnited States
-
Bristol-Myers SquibbCompletedNonalcoholic Steatohepatitis | Liver Fibrosis | Nonalcoholic Fatty Liver Disease (NAFLD)United States, Japan